We Invest Early
Acquiring Drug Assets, Not Companies
We source, partner and finance drug assets in the early stages of preclinical and clinical development, and assume, together with our partner companies, full responsibility for value creation by advancing the assets through further development to proof-of-concept and exit. We have expertise in small molecules, biologics, as well as cell and gene therapies across most therapeutic areas. We are hands-on investors, and source and operate our investments globally. Investing early combined with our de-risking capabilities creates an opportunity for superior investment returns.